Prima-Med, Methenolone Enanthate, 100 mg/ml, 10 ml

Methenolone Enanthate 100 mg/ml by Bioniche Pharma is an extended-release parenteral anabolic formulation derived from dihydrotestosterone (DHT). Formulated by Bioniche Pharma with an enanthate ester chain to deliver smooth, sustained active availability, Bioniche Pharma Methenolone Enanthate provides lean tissue-building properties without estrogenic conversion or $17\alpha$-alkylated liver toxicity.

CLINICAL PHARMACOLOGY & MECHANISM OF ACTION

Methenolone Enanthate by Bioniche Pharma functions by binding selectively to intracellular androgen receptors in target tissues, steering systemic nitrogen balance toward cellular protein synthesis. As a non-aromatizable DHT derivative, Bioniche Pharma Methenolone Enanthate exhibits zero estrogenic activity, preventing risks of gynecomastia and fluid retention while encouraging quality lean muscle accretion.

INDICATIONS & CLINICAL USE

• Palliative clinical care for postmenopausal female patients presenting with advanced, hormone-responsive breast cancer utilizing Bioniche Pharma formulations.
• Anabolic support and recovery during rehabilitation following major surgery, physical trauma, or catabolic wasting states under Bioniche Pharma treatment protocols.
• Supportive management for growth delay disorders under specialized endocrinological supervision.

CONTRAINDICATIONS

• Male individuals with confirmed or suspected prostate carcinoma or male breast cancer.
• Female breast carcinoma complicated by severe hypercalcemia (elevated serum calcium levels).
• Severe renal dysfunction or advanced hepatic pathology.
• Pregnancy and nursing due to severe risks of fetal harm, developmental toxicity, and endocrine disruption.
• Known hypersensitivity or allergic response to Methenolone Enanthate, carrier oils, or inactive compounding excipients in Bioniche Pharma preparations.

PRECAUTIONS & METABOLIC MONITORS

• Glycemic Monitoring: Anabolic agents can modify peripheral insulin sensitivity and glucose clearance. Diabetic patients treated with Bioniche Pharma Methenolone Enanthate should check blood glucose levels frequently, as anti-diabetic medication dosages may need adjustment.
• Pediatric Caution: Heightened clinical vigilance is required in young patients receiving Bioniche Pharma products due to increased sensitivity to androgenic effects and the risk of premature epiphyseal plate fusion.
• Lipid & Hepatic Surveillance: Periodic evaluation of serum lipid fractions (HDL and LDL cholesterol) and baseline liver function parameters is advised during Bioniche Pharma therapy.

ADVERSE REACTIONS

• Dermatological & Androgenic: Low incidence of androgenic events including mild acne vulgaris, heightened sebum production, increased facial or body hair growth (hirsutism), and acceleration of androgenetic alopecia associated with Bioniche Pharma administration.
• Gastrointestinal & Neurological: At elevated dosages, mild central nervous system stimulation or gastrointestinal effects may arise, such as diarrhea, restlessness, heightened excitation, or sleep disturbances (insomnia).
• Endocrine: Dose-dependent suppression of pituitary gonadotropin release during extended Bioniche Pharma Methenolone Enanthate administration.

DOSAGE & ADMINISTRATION

Methenolone Enanthate by Bioniche Pharma is designed exclusively for deep intramuscular injection. Dosing regimens should be individually tailored under qualified clinical direction:

• Adult Males: Standard therapeutic protocols for Bioniche Pharma Methenolone Enanthate typically range from 200 mg to 400 mg weekly